Lyell Immunopharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
26.7%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$7.64next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| PiNACLE Pivotal Trial Data Update (3L+ LBCL) | 31 Dec 2026 |
| LYL273 Phase 1 Clinical Outcomes & End-of-Phase 1 FDA Meeting | 31 Dec 2026 |
| PiNACLE Pivotal Trial Data Readout | 30 Jun 2027 |
Monitoring Framework
Key Performance Indicators
Manufacturing Success Rate for Ronde-cel Quarterly97.0%Target: 95 or higher%
Total Cash, Cash Equivalents, and Marketable Securities Quarterly261MTarget: Sufficient to fund operations into Q2 2027
Grade 2 or Higher Diarrhea/Colitis Rate for LYL273 with GI Prophylaxis Quarterly10.0%Target: 15 or lower%
Watch Items
- PiNACLE 3L+ LBCL Pivotal Trial Enrollment CompletionTrigger: Completion of enrollment of approximately 120 patientsAction: Prepare for pivotal data disclosure in mid-2027 and subsequent BLA submission
- LYL273 Phase 1 Clinical Data Update and End-of-Phase 1 FDA MeetingTrigger: Release of clinical outcomes and FDA alignment on Phase 2 expansionAction: Initiate potential pivotal single-arm Phase 2 trial for metastatic colorectal cancer
- PiNACLE-H2H Phase 3 Randomized Trial ProgressTrigger: Patient dosing milestones and safety reviewsAction: Monitor comparative safety and efficacy against standard-of-care CD19 CAR-T therapies
Research as of 19 Jun 2026